医学
三氧化二砷
急性早幼粒细胞白血病
内科学
不利影响
血癌
完全缓解
胃肠病学
白血病
口炎
化疗
累积剂量
癌症
砷
维甲酸
生物化学
材料科学
化学
冶金
基因
作者
Wing Y. Au,Chi Kong Li,Vincent Lee,HL Yuen,Jeffrey P W Yau,Godfrey C. F. Chan,Shau Yin Ha,Yok–Lam Kwong
摘要
Abstract Four patients (age 3–11 years at diagnosis) with relapsed acute promyelocytic leukemia (APL), 12–38 months from diagnosis, were treated with oral arsenic trioxide (As 2 O 3 ). One patient was treated with oral As 2 O 3 monotherapy and chemotherapy. Three patients failed initial oral or intravenous As 2 O 3 monotherapy were treated with oral As 2 O 3 plus ATRA followed by long‐term oral maintenance (cumulative As 2 O 3 dose 280–2,100 mg). All patients achieved molecular remission, at a median follow up of 122 (10–132) months with no adverse effects. Oral As 2 O 3 , particularly in prolonged maintenance with oral ATRA may obviate the need of stem cell transplantation in relapsed pediatric APL. Pediatr Blood Cancer 2012; 58: 630–632. © 2011 Wiley Periodicals, Inc.
科研通智能强力驱动
Strongly Powered by AbleSci AI